

Fan Luo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2498169/publications.pdf>

Version: 2024-02-01

16
papers

266
citations

1163117

8
h-index

1199594

12
g-index

17
all docs

17
docs citations

17
times ranked

300
citing authors

#	ARTICLE	IF	CITATIONS
1	A Phase Ib Study of Lucitanib (AL3810) in a Cohort of Patients with Recurrent and Metastatic Nasopharyngeal Carcinoma. <i>Oncologist</i> , 2022, 27, e453-e462.	3.7	9
2	CircITGB6 promotes ovarian cancer cisplatin resistance by resetting tumor-associated macrophage polarization toward the M2 phenotype. , 2022, 10, e004029.		44
3	Clinical Significance of Kinetics of Low-Density Lipoprotein Cholesterol and Its Prognostic Value in Limited Stage Small Cell Lung Cancer Patients. <i>Cancer Control</i> , 2021, 28, 107327482110282.	1.8	5
4	Anticancer bispecific antibody R&D advances: a study focusing on research trend worldwide and in China. <i>Journal of Hematology and Oncology</i> , 2021, 14, 124.	17.0	12
5	Lymphocyte activating gene 3 protein expression in nasopharyngeal carcinoma is correlated with programmed cell death-1 and programmed cell death ligand-1, tumor-infiltrating lymphocytes. <i>Cancer Cell International</i> , 2021, 21, 458.	4.1	7
6	Emerging immunological strategies: recent advances and future directions. <i>Frontiers of Medicine</i> , 2021, 15, 805-828.	3.4	5
7	Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer. <i>JAMA Network Open</i> , 2020, 3, e2015748.	5.9	36
8	Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first-line treatment for advanced EGFR-mutant non-small cell lung cancer. <i>Clinical and Translational Medicine</i> , 2020, 10, e33.	4.0	13
9	Prognostic value of serum high-density lipoprotein cholesterol elevation in nonsmall cell lung cancer patients receiving radical surgery. <i>Clinical and Translational Medicine</i> , 2020, 10, e94.	4.0	3
10	Myeloid cell leukemia-1 is an important predictor of survival and progression of small cell lung cancer. <i>Annals of Translational Medicine</i> , 2020, 8, 1589-1589.	1.7	1
11	Nicosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer. , 2019, 7, 245.		66
12	Pemetrexed/carboplatin plus gefitinib as a first-line treatment for EGFR-mutant advanced nonsmall cell lung cancer: a Bayesian network meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591989165.	3.2	10
13	Multi-targeted tyrosine kinase inhibitors as third-line regimen in advanced non-small cell lung cancer: a network meta-analysis. <i>Annals of Translational Medicine</i> , 2019, 7, 452-452.	1.7	9
14	Modification of the tumor response threshold in patients of advanced non-small cell lung cancer treated with chemotherapy plus targeted agents: a pooled study from five clinical trials in one institution. <i>Annals of Translational Medicine</i> , 2019, 7, 253-253.	1.7	1
15	Olanzapine-Based Triple Regimens Versus Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy: A Network Meta-Analysis. <i>Oncologist</i> , 2018, 23, 603-616.	3.7	17
16	Predictive Value of High Preoperative Serum Total Protein and Elevated Hematocrit in Patients with Non-Small-Cell Lung Cancer after Radical Resection. <i>Nutrition and Cancer</i> , 0, , 1-13.	2.0	1